ArticleScientific reports2017
Flexible and Tunable 3D Gold Nanocups Platform as Plasmonic Biosensor for Specific Dual LSPR-SERS Immuno-Detection.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Review
- Surface-Functionalizing Strategies for Multiplexed Molecular Biosensing: Developments Powered by Advancements in Nanotechnologies.Nanomaterials (Basel, Switzerland) · 2024Review
- Dual-Mode Sensing of Fe(III) Based on Etching Induced Modulation of Localized Surface Plasmon Resonance and Surface Enhanced Raman Spectroscopy.Nanomaterials (Basel, Switzerland) · 2024Article
- Optical Detection of Cancer Cells Using Lab-on-a-Chip.Biosensors · 2023Review
- Review
- Gold Nanoparticles Based Optical Biosensors for Cancer Biomarker Proteins: A Review of the Current Practices.Frontiers in bioengineering and biotechnology · 2022Review
- Biosensing Applications Using Nanostructure-Based Localized Surface Plasmon Resonance Sensors.Sensors (Basel, Switzerland) · 2021Review
- Extraordinary sensitivity enhancement of Ag-Au alloy nanohole arrays for label-free detection ofBiomedical optics express · 2021Article
- Recent Advances in the Fabrication and Functionalization of Flexible Optical Biosensors: Toward Smart Life-Sciences Applications.Biosensors · 2021Review
- Recent Progress in Optical Sensors for Biomedical Diagnostics.Micromachines · 2020Review
- Composite-Scattering Plasmonic Nanoprobes for Label-Free, Quantitative Biomolecular Sensing.Small (Weinheim an der Bergstrasse, Germany) · 2019Article
- Rectangular plasmonic interferometer for high sensitive glycerol sensor.Scientific reports · 2019Article
- Designing Efficient Low-Cost Paper-Based Sensing Plasmonic Nanoplatforms.Sensors (Basel, Switzerland) · 2018Article
- Noble metal nanostructures in optical biosensors: Basics, and their introduction to anti-doping detection.Trends in analytical chemistry : TRAC · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early medical diagnostic in nanomedicine requires the implementation of innovative nanosensors with highly sensitive, selective, and reliable biomarker detection abilities. In this paper, a dual Localized Surface Plasmon Resonance - Surface Enhanced Raman Scattering (LSPR- SERS) immunosensor based on a flexible three-dimensional (3D) gold (Au) nanocups platform has been implemented for the first time to operate as a relevant "proof-of-concept" for the specific detection of antigen-antibody binding events, using the human IgG - anti-human IgG recognition interaction as a model. Specifically, polydimethylsilane (PDMS) elastomer mold coated with a thin Au film employed for pattern replication of hexagonally close-packed monolayer of polystyrene nanospheres configuration has been employed as plasmonic nanoplatform to convey both SERS and LSPR readout signals, exhibiting both well-defined LSPR response and enhanced 3D electromagnetic field. Synergistic LSPR and SERS sensing use the same reproducible and large-area plasmonic nanoplatform providing complimentary information not only on the presence of anti-human IgG (by LSPR) but also to identify its specific molecular signature by SERS. The development of such smart flexible healthcare nanosensor platforms holds promise for mass production, opening thereby the doors for the next generation of portable point-of-care devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.